Jim Cramer agrees with UBS: The rally in Johnson & Johnson shares to new highs still has room to run. In a note to clients Wednesday, analysts at UBS raised their price target on the healthcare giant to $320 per share from $280. Their bullish view is based on three factors: (1) Top-line growth inflecting from…
AI stocks came roaring back this week as investors worked through another wave of corporate earnings and a surprisingly weak July jobs report . The major averages notched a second straight week of gains, with the Dow Jones Industrial Average and S & P 500 both touching record highs. The blue-chip index closed at a…
Wall Street got back to its winning ways last week after navigating a hawkish Federal Reserve meeting, volatile swings in chip stocks, and a critical round of Big Tech earnings. The Dow Jones Industrial Average rose 1% for the week, snapping a three-week losing streak. The S & P 500 gained 1% last week, while…
It was a tough week for stocks, as investors navigated everything from escalating tensions in the Middle East to key tech earnings reports to healthcare developments. Logging their second straight weekly losses, the S & P 500 slipped 0.6%, while the tech-heavy Nasdaq fell 2.1%. Here’s a closer look at what drove the trading action….
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stocks were mixed on Wednesday . The S & P 500 was basically flat in late afternoon trading, while the Nasdaq was modestly weaker. Once again,…
My top 10 things to watch Friday, June 12 1. Today’s the day. SpaceX. The largest initial public offering of all time, raising $75 billion. We want a 25% to 30% pop at the open. Anything more than that encourages flippers and gives the company a weak shareholder base. Don’t want to see what happened…
Johnson & Johnson is counting on its newly launched psoriasis pill to become its next cash cow. Investors want to know if it can live up to the hype. Icotyde went to market after the Food and Drug Administration approved it in mid-March for moderate to severe plaque psoriasis. The once-a-day drug is the first…
Wall Street’s scorching rally off its wartime lows back to new highs faces a big test this week: a jam-packed earnings calendar. The list of companies reporting stretches from linchpins of the AI trade like Club name GE Vernova to battleground software stocks such as ServiceNow to companies with their pulse on the industrial economy…
As earnings season continues, CNBC’s Jim Cramer on Friday walked investors through next week on Wall Street, highlighting quarterly reports from companies including Netflix, Intel, Capital One Financial and McCormick. “It’s an awfully odd week, this second week of earnings season, as light as the next week is heavy,” Cramer said. “Except for a couple…
Artificial intelligence has become one of the biggest investment stories in the market, helping drive a surge of assets into thematic exchange-traded funds that let retail investors bet on major technology trends. But experts warn that these funds can fall as quickly as they rise. It’s a simple yet important point for investors to keep…
